Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06846437 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Name: JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer — clinical trial record (NCT06846437)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorShanghai JMT-Bio Inc.

Started2025-02-18

View on ClinicalTrials.gov ↗

Amendment history

2025-03-19

Not Yet Recruiting→Recruiting Study Status, Oversight, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-04-30→confirmed 2025-02-18

Study sites0→1

2025-02-20

Original filing

Shanghai JMT-Bio Inc.

31 trials monitored

See all monitored trials

Breast Cancer

5,180 trials monitored

See 256 trials at risk

HER2-Positive Cancer

324 trials monitored

See 21 trials at risk

This study is designed to compare the safety and efficacy of JSKN003 versus T-DM1 in unrespectable locally advanced and/or metastatic HER2-positive breast cancer participants previously treated with trastuzumab and taxane.

Trial Details

NCT Number	NCT06846437
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
Enrollment	228 participants
Start Date	2025-02-18
Primary Completion	2026-10-13 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-03-24